At last, we also demonstrated that the inhibition of miR-31-3p and the upregulation of miR-143 and miR-145 in two KRAS mutated colorectal cancer cell lines determine the significant reduction of cell proliferation and migration after treatment with cetuximab (both p < 0.05), suggesting a possible pharmaceutical target role of these miRs whose modulation could be used in the overcoming, also if partially, the anti-EGFR resistance in mCRC. Here, KRAS is linked to colorectal cancer.